[Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization?].

Article Details

Citation

Copy to clipboard

Lehmann A, Boldt J, Lang J, Isgro F, Blome M

[Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization?].

Anasthesiol Intensivmed Notfallmed Schmerzther. 2003 Sep;38(9):577-82.

PubMed ID

12975736 [ View in PubMed

]

Abstract

Levosimendan, is a new calcium sensitiser with 2 major effects. First, levosimendan acts as a positive inotropic agent by binding calcium dependently to cardiac troponin C. Second, levosimendan activates adenosine triphosphate-regulated potassium (K (ATP)) channels. Thus it has vasodilatory properties and cardioprotective effects at a dose enhancing myocardial contractility. These unique properties of levosimendan might be of great advantage in patients with myocardial ischemia simultaneously requiring inotropic support. The concept of perioperative inoprotection is presented in 6 patients with acute ischemia undergoing emergent cardiac surgery.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Levosimendan	Troponin C, slow skeletal and cardiac muscles	Protein	Humans	Yes	Potentiator	Details